Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
Benitec Biopharma Inc
Benitec Biopharma Inc BNTC | 0.00 |
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:
BNTC) with a Outperform rating and announces Price Target of $16.
